VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Curis Executive Compensation (FY25)

CRIS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
James Dentzer
Latest say-on-pay support
=
May 20, 2025
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Curis

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 28, 2026Latest filing (DEF 14A): April 21, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Curis brief$1,500Get the executive brief
Velarion Intel, one year, every company
131 figures on this page: 123 cited to the filing that reported them, 8 calculated from figures it prints. See the citations

More on Curis

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — James Dentzer: $1,973,386 → $1,659,756 (15.9% lower)
Say-on-pay support: 89.3% → 93.4% (4.1 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Curis' chief executive and what were they paid?
James Dentzer was paid $1,659,756 in total compensation as President and Chief Executive Officer for fiscal 2025. Dentzer's total was 15.9% lower than the $1,973,386 reported for fiscal 2024.
What was Curis' say-on-pay result?
The say-on-pay proposal drew 93.4% of votes cast for or against in favor at the meeting held May 20, 2025 for fiscal 2024.
Which companies are in Curis' peer group?
The disclosed peer group includes Akebia Therapeutics, Inc., C4 Therapeutics, Inc., Cara Therapeutics, Inc., Chimerix, Inc. and G1 Therapeutics, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Dentzer
President and Chief Executive Officer
◇——◇◇—◇◇
Diantha Duvall
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Dentzer
President and Chief Executive Officer
◇——◇◇—◇◇
Diantha Duvall
Chief Financial Officer
◇——◇◇—◇◇
Jonathan Zung
Chief Development Officer
◇——◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Dentzer
President and Chief Executive Officer
◇——◇◇—◇◇
Jonathan Zung
Chief Development Officer
◇——◇◇—◇◇
Diantha Duvall
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Dentzer
President and Chief Executive Officer
◇——◇◇—◇◇
Jonathan Zung
Chief Development Officer
◇——◇◇—◇◇
Diantha Duvall
Chief Financial Officer
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James DentzerOption◇—◇January 28, 2035
Option◇—◇January 18, 2034
Option◇—◇January 19, 2033
Option◇—◇January 27, 2032
Jonathan ZungOption◇—◇January 28, 2035
Option◇—◇January 18, 2034
Option◇—◇April 30, 2033
Diantha DuvallOption◇—◇January 28, 2035
Option◇—◇January 18, 2034
Option◇—◇January 19, 2033
Option◇—◇July 25, 2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Martyn D. Greenacre
Board chair
◇—◇———◇
Kenneth I. Kaitin, Ph.D
◇—◇———◇
Marc Rubin, M.D
◇—◇———◇
John A. Hohneker, M.D
◇—◇———◇
Anne E. Borgman, M.D
◇—◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • Akebia Therapeutics, Inc. AKBA
  • C4 Therapeutics, Inc. CCCC
  • Cara Therapeutics, Inc. CARA
  • Chimerix, Inc. CMRX
  • G1 Therapeutics, Inc. GTHX
  • KALA Bio, Inc. KALA
  • MEI Pharma, Inc. MEIP
  • Omeros Corporation OMER

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024May 20, 2025=◇◇◇
2023May 21, 2024=◇◇◇
2021May 26, 2022=◇◇◇
2020May 27, 2021=◇◇◇
2019June 4, 2020=◇◇◇
2018May 23, 2019=◇◇◇
2017May 15, 2018=◇◇◇
2016May 16, 2017=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- James Dentzer (President and Chief Executive Officer), FY2025 total compensation $1,659,756 (base salary $672,200) [exec_comp, SEC accession 0001108205-26-000053, filed 2026-04-21]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Curis files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Curis disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Curis sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Curis' disclosed peer group is defensible, who names Curis back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
131 figures on this page: 123 cited to the filing that reported them, 8 calculated from figures it prints.
123 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001108205-26-000053
    Director Compensation · Outstanding Equity Awards at Fiscal Year-End · Summary Compensation Table
  2. 0001108205-25-000053
  3. 0001108205-24-000047
    E. Dentzer 2,301,631 127,272 1,644,248 2.
  4. 0001108205-24-000025
    Summary Compensation Table
  5. 0001193125-22-166212
    M.D. 23,717,040 22,142,384 23,336,352 2: A nonbinding advisory proposal on the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes
  6. 0001193125-21-179839
  7. 0001193125-20-165678
  8. 0001193125-19-161261
  9. 0001193125-18-168094
    Abstain 119,964,114 22,533,223 218,106 5: A nonbinding advisory proposal on the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes
  10. 0001193125-17-178009
    7,633,456 1,406,540 95,503 30,614,014 4: A non-binding advisory proposal on the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Curis executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CRIS (accessed 2026).
Short form: data: Velarion

The paid brief for Curis

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Curis and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Curis discloses

The companies named in CRIS's own disclosed peer group.

Akebia Therapeutics, Inc.C4 Therapeutics, Inc.Cara Therapeutics, Inc.Chimerix, Inc.G1 Therapeutics, Inc.KALA Bio, Inc.Omeros Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy